Meanwhile, in the colon...

Meanwhile, in the colon - that long, underappreciated hallway of your digestive tract - geography is apparently doing some very rude things. A new CDC QuickStats report maps age-adjusted colorectal cancer death rates by state in 2024, and the big takeaway is not subtle: where you live in the United States still has way too much say in your odds of dying from this disease.¹

This is one of those papers that is less "lab mice in tiny goggles" and more "the spreadsheet is screaming." And honestly, public health data can be just as dramatic when you know what you're looking at.

A map, a pattern, and a pretty uncomfortable question

The CDC report is short. Very short. It is a QuickStats, which means it gets in, drops the numbers, and leaves like a consultant who billed by the hour. But the message lands.

In 2024, age-adjusted colorectal cancer death rates varied notably across states. According to the report, the highest rates clustered in parts of the South and Appalachia, while lower rates appeared in several Western and Northeastern states.¹ That's not random noise. That's a pattern.

And patterns in cancer mortality usually mean systems are involved - screening access, insurance coverage, poverty, diet, smoking, primary care availability, rural hospital closures, structural racism, treatment delays, and the small matter of whether a person can actually get to a colonoscopy without turning it into a three-job logistics startup.

Colorectal cancer is one of the more preventable major cancers, which makes this extra frustrating. Unlike a lot of tumors that lurk like stealth mode villains, colon cancer often starts as a polyp that can be found and removed before it becomes a full-blown problem. In startup terms, this is a bug you can catch in beta. And yet the production outage keeps happening.

Why this matters more than a map nerd convention

A state-by-state mortality map is not just trivia for epidemiologists. It tells you where prevention and treatment pipelines are leaking.

Deaths from colorectal cancer reflect more than biology. They reflect who gets screened on time, who gets weird symptoms taken seriously, who can afford follow-up care, and who ends up diagnosed when the cancer is still manageable versus when it has already expanded its market share to the liver.

That last part matters because colorectal cancer outcomes change a lot with stage at diagnosis. Screening has been associated with reduced incidence and mortality, especially because it can prevent cancer by removing precancerous lesions.² The U.S. Preventive Services Task Force recommends screening for average-risk adults starting at age 45, a shift made partly because cases in younger adults have been climbing.³

So when death rates remain high in certain regions, that suggests the health system is not shipping updates evenly.

The colon cancer plot twist nobody ordered

Here is the extra wrinkle: while overall colorectal cancer mortality has declined over the long run, early-onset colorectal cancer - meaning cases in younger adults - has become a genuine concern.⁴⁵ That trend has rattled oncologists because it means the old mental model of colon cancer as a disease mostly for older adults is getting stale.

Reviews in the last few years have pointed to a messy mix of possible drivers: obesity, diet, sedentary behavior, microbiome changes, inflammation, and environmental exposures.⁴⁵ Science has not tied this up with a neat bow yet, because cancer biology rarely behaves like a well-managed product roadmap.

At the same time, disparities remain stubborn. Rural patients often face longer travel times, lower screening uptake, and less access to specialty care. Racial and socioeconomic inequities also shape who gets diagnosed early and who doesn't.⁶⁷

So this CDC map is doing something deceptively simple. It is showing where all those forces may be adding up to the worst outcomes.

What could actually change this?

The obvious answer is "more screening," but that phrase hides a whole lot of operational drama.

Yes, screening matters. Colonoscopy is the headline act, but stool-based tests can also help increase participation when colonoscopy is harder to access or less acceptable to patients.³ The trick is not just offering a test. It is building a system where the test happens, the result gets followed up, and treatment starts fast if something looks bad. Otherwise you've built a landing page with no checkout flow.

States with higher death rates may benefit from targeted investment in screening programs, patient navigation, Medicaid expansion, rural oncology access, and awareness campaigns aimed at both older adults and younger people with symptoms. Blood in the stool, unexplained weight loss, changed bowel habits - these should not be waved off as "probably stress" or "the tacos fighting back."

There is also a policy angle here. Colorectal cancer mortality is not only a medical issue. It is an infrastructure issue. If one state has much worse outcomes than another, that is not fate. That is a fixable product failure at the population level.

The bigger takeaway

This paper does not unveil a miracle drug or a sexy new cell therapy with a name that sounds like a robot law firm. It does something quieter and, in its own way, more useful. It points directly at where the country is still failing people.

Cancer data like this can feel dry until you remember that every "rate" is made of actual lives, actual families, actual missed chances to catch disease earlier. The map is not the story. The story is that colorectal cancer is often detectable, often preventable, and still not prevented nearly evenly enough.

That should annoy all of us.

If this report gets policymakers, clinicians, and health systems to focus on the states carrying the heaviest burden, then a tiny QuickStats chart will have pulled off a pretty solid public health product launch.

References

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.